Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease.

ABSTRACT:

Background and aim

Adalimumab is administered and dosed using a standardized treatment regimen. Although therapeutic drug monitoring (TDM) may help optimize treatment efficacy, the lower cut-off concentration of adalimumab needed to retain disease remission has not been established. This cross-sectional study of patients with Crohn's disease on stable medication aimed to determine a lower therapeutic drug concentration threshold of adalimumab associated with biochemical disease remission.

Methods

C-reactive protein (CRP) and fecal calprotectin were used as established markers and albumin as an explorative marker of disease activity. Time since introduction, treatment interval, drug dosage, serum drug concentration and antidrug antibodies, disease duration, age, and sex were

SUBMITTER: Carlsen A 

PROVIDER: S-EPMC7273736 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature